Replimune Presents Updated Interim Results from the ARTACUS
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients...
Stay updated with breaking news from Nasdaq Repl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients...
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $13.34 and last traded at $13.34, with a volume of 529686 shares traded. The stock had previously closed at $14.29. Analyst Ratings Changes Separately, HC Wainwright reduced their price objective on […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $15.33 and last traded at $15.41, with a volume of 25155 shares traded. The stock had previously closed at $16.17. Analyst Ratings Changes Separately, HC Wainwright dropped their target […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 2,604 put options on the company. This represents an increase of 110% compared to the average volume of 1,239 put options. Replimune Group Stock Performance REPL traded down $0.25 during trading on Wednesday, hitting […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shares traded down 3.2% during trading on Friday . The stock traded as low as $15.93 and last traded at $15.98. 125,998 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 563,938 shares. The stock had previously closed at $16.50. […]